Have you been diagnosed with, or are you at risk for (diabetic, obese, have high blood pressure), nonalcoholic steatohepatitis (NASH)? If so, you may be able to participate in a study to evaluate an oral investigational drug for NASH with fibrosis. This study involves approximately 20 visits over a year and a half. Compensation is provided.
IRB:SSU00117092 - Enanta Pharmaceuticals Inc - EDP 305-102, A PHASE 2b RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING SAFETY AND EFFICACY OF EDP-305 IN SUBJECTS WITH LIVER-BIOPSY PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) (Pro00040905)
MEET THE RESEARCHER
Mordechai Rabinovitz, MD, is a Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh. A graduate of Tel-Aviv University in Israel, Dr. Rabinovitz’s research interests include assessment and treatment of chronic viral hepatitis as well as developing new therapies for non-alcoholic fatty liver disease.